A Phase 2 interventional study of Abatacept and Placebo in Myositis and Interstitial Lung Disease, sponsored by Rohit Aggarwal, MD. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-07.
Sponsored by Rohit Aggarwal, MD · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Myositis with a site in United States — 26 open to participants now, 32 under way, 6 of them phase 3. Myositis · United States.
Among the 78 studies in Myositis with a site in United States, this one is the 36th largest by enrollment of the 56 interventional ones that give a count, is one of 4 that started in 2018, is one of 18 in phase 2, and was the 29th registered.
216 studies on the registry are indexed under Myositis; 101 are open to participants now.
Browse Myositis studies →26 of the 78 studies in Myositis with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18+ · Healthy volunteers
Fate Therapeutics · Sites in United States
Ages 18–70
Cartesian Therapeutics · Sites in United States
Ages 18+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Australia, Germany and 3 more countries
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 72 Myositis studies recruiting now, 28 (39%) set no upper age limit and 36 (50%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 30 · Phase 3 13 · Phase 4 3
First in 1992; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 30 across 142 interventional studies indexed under Myositis.
Median enrollment 34 across the 56 interventional studies, 580 across the 21 observational. Of the 42 that completed or were terminated, 18 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 78 have an industry lead sponsor. The 10 most frequent:
Rohit Aggarwal, MD is the lead sponsor of 3 studies on the registry; none are open to participants now.
Rohit Aggarwal, MD has 2 studies filed under Myositis — fewer than ten, so there is no comparison to draw.
8 of the studies in Myositis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06284954argenxA Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis | 2026-11 |
| NCT06375993Adicet TherapeuticsA Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | 2026-12 |
| NCT06152172David PorterCARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 | 2027-02 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
| NCT06479863Austin Neuromuscular CenterEfficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis | 2027-05-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 78 studies in Myositis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomized, controlled pilot trial to evaluate the efficacy and safety of subcutaneous Abatacept in treating interstitial lung disease associated with the anti-synthetase syndrome.
This is a proof of concept study to evaluate the efficacy, safety and tolerability of abatacept in Syn-ILD in a multi-center randomized, placebo-controlled 6-month (24-week) pilot study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
SOC therapy (IS) therapy:
If the enrolling physician is planning to discontinue current IS agent or steroid before clinical trial, then following is required prior to Visit 1.
Medication Washout Period methotrexate 4 weeks Other IS agent (e.g. azathioprine, cyclosporine, tacrolimus, leflunomide, mycophenolate mofetil) 4 weeks IVIg or cyclophosphamide 3 months rituximab 6 months infliximab or adalimumab 8 weeks glucocorticoids 2 weeks etanercept 2 weeks anakinra 1 week pirfenidone 4 weeks
Exclusion Criteria:
A patient will be excluded if any of the following Exclusion Criteria are met:
Severe end stage lung disease:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subcutaneous placebo injection weekly for 24 weeks.
Other: Placebo
Subcutaneous injection of abatacept 125 mg weekly for 24 weeks. 24 week optional follow up phase all subjects receive abatacept 125 mg weekly.
Drug: Abatacept
Abatacept 125mg subcutaneous weekly
Also known as: Orencia
Placebo
% Predicted Forced Vital Capacity (FVC) Absolute Change
The primary outcome criteria for efficacy will be the absolute change of % predicted FVC from the baseline visit to week 24 between the 2 treatment arms (SOC/placebo vs. SOC/Abatacept).
Time frame: 24 Weeks
Time to Progression Free Survival
The first occurrence of any of the following: death or lung transplantation or decline in % predicted FVC ≥ 10% or decline in % predicted FVC ≥ 5% with a decline in % predicted DLCO ≥ 15%
Time frame: 48 weeks
Comparison of Change in Patient Reported Dyspnea Scores (University of California San Diego Shortness of Breath Questionnaire)
Measured by University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ) (range 0-120, higher score is worsening dyspnea).
Time frame: 24 weeks
Time to Improvement in % Predicted FVC ≥10%
Comparison of percent predicted FVC results from pulmonary function tests from baseline to week 48. Improvement is defined as a % predicted FVC change ≥10%
Time frame: 48 weeks
Subjects were enrolled from four clinical sites between June 2017 through May 2021.
| Milestone | Placebo | Abatacept |
|---|---|---|
| Started | 11 | 9 |
| Completed | 11 | 8 |
| Not completed | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Milestone | Placebo | Abatacept |
|---|---|---|
| Started | 11 | 8 |
| Completed | 9 | 7 |
| Not completed | 2 | 1 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Death | 0 | 1 |
The primary outcome criteria for efficacy will be the absolute change of % predicted FVC from the baseline visit to week 24 between the 2 treatment arms (SOC/placebo vs. SOC/Abatacept).
| % predicted FVC | Placebo | Abatacept |
|---|---|---|
| % Predicted Forced Vital Capacity (FVC) Absolute Change | -1.70 (-5.90 to 2.50) | -2.05 (-6.97 to 2.87) |
The first occurrence of any of the following: death or lung transplantation or decline in % predicted FVC ≥ 10% or decline in % predicted FVC ≥ 5% with a decline in % predicted DLCO ≥ 15%
| Weeks | Placebo | Abatacept |
|---|---|---|
| Time to Progression Free Survival | 27.71 (12.71 to 46.86) | 16.86 (15.36 to 34.93) |
Measured by University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ) (range 0-120, higher score is worsening dyspnea).
| score on a scale | Placebo | Abatacept |
|---|---|---|
| Comparison of Change in Patient Reported Dyspnea Scores (University of California San Diego Shortness of Breath Questionnaire) | -4.59 (-15.54 to 6.36) | 3.20 (-8.86 to 15.26) |
Comparison of percent predicted FVC results from pulmonary function tests from baseline to week 48. Improvement is defined as a % predicted FVC change ≥10%
| weeks | Placebo | Abatacept |
|---|---|---|
| Time to Improvement in % Predicted FVC ≥10% | 17.86 (9.86 to 25.86) | 11.86 (11.86 to 11.86) |
Collected over Adverse events were collected from Baseline (week 0) through end of study Visit 5 (week 48). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/11 (0%) | 0/11 (0%) | 5/11 (45.5%) |
| Abatacept | 1/20 (5%) | 3/20 (15%) | 6/20 (30%) |
| Event | Placebo | Abatacept |
|---|---|---|
| Respiratory FailureRespiratory, thoracic and mediastinal disorders | 0/11 | 1/20 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 0/11 | 1/20 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/11 | 1/20 |
| Event | Placebo | Abatacept |
|---|---|---|
| Excessive bruisingBlood and lymphatic system disorders | 2/11 | 1/20 |
| Sinus TachycardiaCardiac disorders | 2/11 | 0/20 |
| NauseaGastrointestinal disorders | 2/11 | 0/20 |
| Upper Respiratory InfectionInfections and infestations | 2/11 | 3/20 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/11 | 3/20 |
| diarrheaGastrointestinal disorders | 0/11 | 3/20 |
| Eye InfectionInfections and infestations | 0/11 | 1/9 |
| Deceased lymphocyte countInvestigations | 0/11 | 2/20 |
| Chest painCardiac disorders | 0/11 | 2/20 |
| renal calculiRenal and urinary disorders | 0/11 | 2/20 |
| Age, Continuous(years) | Placebo | Abatacept | Total |
|---|---|---|---|
| Mean | 55.95 ± 6.87 | 51.56 ± 10.69 | 53.98 ± 8.83 |
| Sex: Female, Male(Participants) | Placebo | Abatacept | Total |
|---|---|---|---|
| Female | 7 | 4 | 11 |
| Male | 4 | 5 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Abatacept | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 11 | 9 | 20 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Abatacept | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 10 | 7 | 17 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Forced Vital Capacity (FVC) %(%) | Placebo | Abatacept | Total |
|---|---|---|---|
| Median | 61.0 (53.0 to 80.0) | 66.0 (49.0 to 68.5) | 63.5 (52.3 to 72.5) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2018 to primary completion in May 2022, 52 months.
Results were first posted in Jan 2025, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept
Rohit Aggarwal, MD